Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on SGLT 2 Inhibitor. These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Novel 3-step synthesis for Dapagliflozin ensures high yield and purity. Cost-effective manufacturing solution for global pharmaceutical supply chains.
Novel one-pot method for (5-bromo-2-chlorophenyl)(4-ethoxyphenyl)methanone. High purity, reduced steps, eco-friendly process for API manufacturing.
Advanced Lewis acid catalysis for SGLT2 inhibitor intermediates. Reduces waste salt and enhances selectivity for reliable pharmaceutical intermediate supply chains.
Patent CN107540648A reveals a novel route for Dapagliflozin offering high purity and safety. This report analyzes cost reduction in API manufacturing and supply chain reliability.
Novel synthetic route for I-D1-6 diabetes inhibitor intermediate. Scalable process reduces raw material dependency and ensures supply chain stability for global pharmaceutical manufacturers.
Patent CN103524469A discloses a high-yield synthesis for C-glucoside SGLT2 inhibitors, offering improved purity and scalable manufacturing for pharmaceutical supply chains.
Patent CN109553609A reveals a safer Canagliflozin synthesis route. Achieve high purity without alpha-isomers and reduce operational costs in pharmaceutical intermediate manufacturing.
Patent CN113200860B reveals high-purity SGLT2 inhibitor intermediate via flow chemistry. Reduces cost and improves supply chain reliability for pharmaceutical manufacturing.